Showing 7531-7540 of 8880 results for "".
- BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Yearshttps://practicaldermatology.com/news/be-heard-bimekizumab-shows-sustained-relief-in-hs-symptoms-through-3-years/2484274/Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years. <
- Topical Caffeine May Provide Hair Growth Benefit for Alopecia: Studyhttps://practicaldermatology.com/news/topical-caffeine-may-provide-hair-growth-benefit-for-alopecia-study/2484243/Topical caffeine may be a promising adjunct treatment for hair loss, according to a systematic review published in the Journal of Drugs in Dermatology. The analysis assessed original studies investigating caffeine’s effects on hair growth across multiple fo
- Study IDs Additional Risk Allele in Allopurinol-Induced Cutaneous Reactions in US Patientshttps://practicaldermatology.com/news/study-ids-additional-risk-allele-in-allopurinol-induced-cutaneous-reactions-in-us-patients/2484235/A recently published genetic association study has identified HLA-A34:02 as an independent allele significantly associated with severe cutaneous adverse reactions (SCARs) to allopurinol in a US-based cohort. Researchers from
- Red Light PDT with 10% ALA Gel Demonstrates Efficacy for Superficial BCChttps://practicaldermatology.com/news/red-light-pdt-with-10-ala-gel-demonstrates-efficacy-for-superficial-bcc/2484215/
- Sarecycline Monotherapy Delivers in Real-World Acne Studyhttps://practicaldermatology.com/news/sarecycline-monotherapy-delivers-in-real-world-acne-study/2484121/A post hoc analysis of the PROSES study found that oral sarecycline monotherapy is as effective as combination therapy with topicals in treating moderate-to-severe acne vulgaris (AV), based on 12-week outcomes from a real-world U.S. cohort presented by Dr. Hilary B
- Bimekizumab Maintains Flare Control in HS Through 2 Yearshttps://practicaldermatology.com/news/bimekizumab-maintains-flare-control-in-hs-through-2-years/2484119/Bimekizumab provides sustained control of disease flares in patients with moderate-to-severe hidradenitis suppurativa (HS), with more than 83% of patients remaining flare-free over 96 weeks, according to interim results from the BE HEARD EXT study presented by Dr. H
- Combination of Clascoterone 1% and Adapalene 0.3% Shows Promise for Acnehttps://practicaldermatology.com/news/combination-of-clascoterone-1-and-adapalene-03-shows-promise-for-acne/2484118/Combination therapy with clascoterone cream 1% and adapalene gel 0.3% significantly improves acne severity and quality of life, while maintaining excellent tolerability in patients with moderate-to-severe acne vulgaris, according to a 16-week pilot study presented
- 487-GEP Test Identifies Optimal Systemic Therapy for ADhttps://practicaldermatology.com/news/487-gep-test-identifies-optimal-systemic-therapy-for-ad/2484115/A 487-gene expression profile (487-GEP) test may help personalize systemic therapy selection for patients with atopic dermatitis (AD), according to results from a prospective, multicenter trial presented by Dr. Jonathan Silverberg et al at the 2025 Fall Clinical De
- Skin Cancer Champions Launches Integrated Public, Private Communityhttps://practicaldermatology.com/news/skin-cancer-champions-launches-integrated-public-private-community/2484106/The Skin Cancer Champions organization, led by dermatologists Emily Ruiz, MD, MPH, and Chrysalyne Schmults, MD, MSce, FAAD, announced the official launch of its integrated public and private community at skincancerchampions.org. The public platform expands the group’s reach by offering edu
- Study: Semaglutide Improves PASI Scoreshttps://practicaldermatology.com/news/study-semaglutide-improves-pasi-scores/2484098/Semaglutide may offer dual dermatologic and metabolic benefits in patients with psoriasis and obesity, even in the absence of diabetes, according to a 6-month prospective cohort study in Clinical and Experimental Dermatology.